How to buy Vor Biopharma (VOR) stock

Vor Biopharma Inc complete an upsized $176.9 million IPO, offering 9.83 million shares at $18 each.

The stock opened at $42.02 was jumped 104.9% in early action.

Vor Biopharma stock price (NASDAQ: VOR)

Use our graph to track the performance of VOR stocks over time.

Vor Biopharma shares at a glance

• Key figures

Information last updated 2021-07-24.

Latest market close	$21.02
52-week range	$12.97 - $59.00
50-day moving average	$19.10
200-day moving average	$29.48
Wall St. target price	$47.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Vor Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Vor Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vor Biopharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vor Biopharma price performance over time

Historical closes compared with the close of $21.02 from 2021-05-26

1 week (2021-07-14)	N/A
1 month (2021-06-25)	-1.31%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

Vor Biopharma financials

Gross profit TTM	$0
Return on assets TTM	-15.81%
Return on equity TTM	-35.81%
Profit margin	0%
Book value	$7.27
Market capitalisation	$482.7 million

TTM: trailing 12 months

Shorting Vor Biopharma shares

There are currently 1.6 million Vor Biopharma shares held short by investors – that's known as Vor Biopharma's "short interest". This figure is 14.4% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Vor Biopharma shares can be evaluated.

Vor Biopharma's "short interest ratio" (SIR)

Vor Biopharma's "short interest ratio" (SIR) is the quantity of Vor Biopharma shares currently shorted divided by the average quantity of Vor Biopharma shares traded daily (recently around 146394.74654378). Vor Biopharma's SIR currently stands at 10.85. In other words for every 100,000 Vor Biopharma shares traded daily on the market, roughly 10850 shares are currently held short.

To gain some more context, you can compare Vor Biopharma's short interest ratio against those of similar companies.

• ADC Therapeutics (ADCT.US): 22.69
• Oncolytics Biotech (ONCY.US): 1.21
• CytomX Therapeutics (CTMX.US): 7.73

However Vor Biopharma's short interest can also be evaluated against the total number of Vor Biopharma shares, or, against the total number of tradable Vor Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vor Biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Vor Biopharma shares in existence, roughly 40 shares are currently held short) or 0.1018% of the tradable shares (for every 100,000 tradable Vor Biopharma shares, roughly 102 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Vor Biopharma.

Find out more about how you can short Vor Biopharma stock.

Vor Biopharma share dividends

We're not expecting Vor Biopharma to pay a dividend over the next 12 months.

Vor Biopharma overview

Vor Biopharma, Inc. , early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Vor Biopharma is owned by insiders or institutions?
Currently 2.382% of Vor Biopharma shares are held by insiders and 82.787% by institutions. How many people work for Vor Biopharma?
Latest data suggests 92 work at Vor Biopharma. When does the fiscal year end for Vor Biopharma?
Vor Biopharma's fiscal year ends in December. Where is Vor Biopharma based?
Vor Biopharma's address is: 100 Cambridgepark Drive, Cambridge, MA, United States, 02140